Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Dupilumab

Brand: Dupixent®
NICE TA: 534
Indication: Treatment of moderate to severe atopic dermatitis
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
• the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
• the company provides dupilumab according to the commercial arrangement.
Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:
• at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
• at least a 4‑point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA 534 - Dupilumab for treating moderate to severe atopic dermatitis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red